Cost-Effectiveness Of Ombitasvir/Paritaprevir/Ritonavir With Or Without Dasabuvir For The Treatment Of Chronic Hepatitis C Patients Infected With Genotype 1 Or 4 In France
Nov 1, 2016, 00:00
10.1016/j.jval.2016.09.404
https://www.valueinhealthjournal.com/article/S1098-3015(16)31771-5/fulltext
Title :
Cost-Effectiveness Of Ombitasvir/Paritaprevir/Ritonavir With Or Without Dasabuvir For The Treatment Of Chronic Hepatitis C Patients Infected With Genotype 1 Or 4 In France
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)31771-5&doi=10.1016/j.jval.2016.09.404
First page :
A416
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
380